Accredited Investors Employee Shareholders Institutions Private Companies Who We Serve Trading and InvestingData SolutionsPrivate Asset Custody Institutional TradingForge ProTrade private companies with Forge’s institutional brokerage toolBrowse CompaniesIndividual InvestingForge MarketsFind new private company investment opportunitiesForge DataAnalyze private markets via Forge’s intuitive web applicationForge Private Market IndexMonitor a benchmark for actively traded private companies Forge Accuidity Private Market IndexInvest in an institutionally-managed diversified basket of private companies (QPs only)Self-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRASolutions All InsightsPrivate Market ReportsMarket InsightsBuying and Selling Pre-IPO All ReportsPrivate Market Updates Forge Investment OutlookStartup News and TrendsPrivate Market Data and AnalyticsTech IPO Calendar for 2024Private Market ExplainedBuying Pre-IPO SharesSelling Pre-IPO Shares Glossary Videos FAQsInsights About Us Leadership Investor Relations People & Culture Careers About

Frontier Medicines Stock

Q: How to sell Frontier Medicines stock?

If you hold private company shares of Frontier Medicines - whether as an employee or an early investor - Forge can help you sell them. 1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have. 2. Indicate your interest to sell your Frontier Medicines stock on our platform. 3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.

frontiermeds.comHealthcare / BioTech & PharmaFounded: 2018Funding to Date: $255.5MM

Frontier Medicines is a precision medicine company that develops breakthrough medicines for patients. Specifically, the company focuses on developing therapies for previously undruggable disease-causing proteins. Through its proprietary Frontier Platform, the company combines scientific approaches that include chemoproteomics, covalent drug discovery, and machine learning. Frontier Medicines was founded in 2018 by Chris Varma Ph.D and headquartered in San Francisco, CA.

Buy or sell Frontier Medicines stockLearn more about Frontier Medicines IPO

OverviewFinancingsValuation

Enterprise Value

Access Frontier Medicines’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Frontier Medicines.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

Frontier Medicines investors also invested in these private companies

Ra Capital Management

X-energy, Element Biosciences, Mindtickle, BioAge, Freenome, Capstan Therapeutics, Synthego, Sionna Therapeutics, FogPharma, Bicara Therapeutics

Woodline Partners

Kriya Therapeutics, Scorpion Therapeutics, Frontier Medicines, Obsidian Therapeutics, SmartNews, Endeavor BioMedicines, Septerna, Odyssey Therapeutics

Deerfield Management

Insilico Medicine, LetsGetChecked, FogPharma, Epic Sciences, Bicara Therapeutics, Lark Technologies, Frontier Medicines, Intus Care, Crossover Health, Twill

Deep Track Capital

Carmot Therapeutics, Frontier Medicines, Hemab Therapeutics, Obsidian Therapeutics, Avenzo, Apogee Therapeutics, Septerna

DCVC Bio

Frontier Medicines, Totus Medicines, Unlearn, Sabanto

ArrowMark Partners

Formation Bio, Freenome, Zenas BioPharma, Frontier Medicines, Checkerspot, Evolve, Binx Health

Johnson & Johnson Innovation

HistoSonics, ArteraAI, Capstan Therapeutics, Vedanta Biosciences, Accent Therapeutics, Frontier Medicines, RefleXion Medical, Obsidian Therapeutics, Procyrion, Binx Health

Droia Ventures

Accent Therapeutics, Frontier Medicines

Sphera Funds Management

Neurona Therapeutics, Frontier Medicines

MPM BioImpact

NextPoint Therapeutics, Frontier Medicines

Galapagos

Frontier Medicines

Driehaus Capital Management

Frontier Medicines, Alterome Therapeutics

Berkeley Catalyst Fund

Frontier Medicines

Team

Management Team

Chris Varma Ph.D

Co-Founder, Chief Executive Officer & President

Roberto Zoncu Ph.D

Co-Founder & Advisor

Daniel Nomura Ph.D

Co-Founder & Advisor

Johannes Hermann Ph.D

Chief Technology Officer

Monique Bobadilla

Chief People and Culture Officer

Kevin Webster Ph.D

Chief Scientific Officer

Andrew Krivoshik MD

Chief Medical Officer

Gregory Chow

Chief Financial Officer

Board Members

Cameron Wheeler Ph.D

Deerfield Management

Derek DiRocco Ph.D

RA Capital Management

Luke Evnin Ph.D

MPM BioImpact

Frontier Medicines stock FAQs

Can you buy Frontier Medicines stock?

As Frontier Medicines is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private company like Frontier Medicines, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not an accredited investor, discover how to begin the process to potentially qualify for new investment opportunities.

How to buy Frontier Medicines stock?

To invest in a private company like Frontier Medicines through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

Create a free account to access Forge’s marketplace.
Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.

Can you sell Frontier Medicines stock?

Yes, you may be able to sell your Frontier Medicines stock, subject to certain conditions. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company's interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.

How to sell Frontier Medicines stock?

If you hold private company shares of - whether as an employee or an early investor - Forge can help you sell them.

Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
Indicate your interest to sell your Frontier Medicines stock on our platform.
Work with your dedicated Private Market Specialist who'll help guide you through every step of the transaction.

Is Frontier Medicines a public company?

No, Frontier Medicines is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.

What is Frontier Medicines’ stock price?

Frontier Medicines is a privately held company and therefore does not have a public stock price. However, you may access Frontier Medicines’ private market stock price with Forge Data.

What is Frontier Medicines’ stock ticker symbol?

Frontier Medicines does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

BioSpace 02/23/2024

Frontier Medicines Raises $80M in Series C, Targets Amgen and BMS in KRAS

Frontier Medicines on Thursday closed its oversubscribed $80 million Series C funding round, which it will use to advance its potentially first-in-class next-generation KRAS blocker FMC-376. The financing brings Frontier’s total capital raised to $235.5 million since its founding, according to the announcement. The funding round was co-led by Deerfield Management Company and Droia Ventures. Galapagos NV, a Belgium-based pharmaceutical company, participated as a strategic investor, along with contributions from MPM Capital, RA Capital Management and DCVC Bio.

Browse More Insights

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.